Skip to main content

Advertisement

Table 4 Analyses of Lymphocyte Subsets in ALNs(a) in Women with LLABCs(b) Undergoing NAC(c): Comparison of Metastatic and Non Metastatic ALNs

From: Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC

Lymphocyte Subsets (n = 33) Groups ALN Median (Range) P Value(g)
CD4+ Non metastatic ALNs (n = 9) 63.0 (43.0-74.0)(e) 0.796
Metastatic ALNs (n = 24) 68.0 (32.0-75.0)
CD8+ Non metastatic ALNs (n = 9) 26.0 (15.4-34.0)(e) 0.121
Metastatic ALNs (n = 24) 20.5 (10.4-40.0)
FOXP3+ Non metastatic ALNs (n = 9) 4.4 (2.9-8.6)(e) 0.736
Metastatic ALNs (n = 24) 4.6 (0.2-10.8)
CTLA-4+ Non metastatic ALNs (n = 9) 16.8 (5.2-100.4)(f) 0.193
Metastatic ALNs (n = 24) 11.0 (0.6-38.6)
PD-1+ (d) Non metastatic ALNs (n = 9) 6.4 (1.4-36.0)(f) 0.408
Metastatic ALNs (n = 7) 12.6 (2.0-72.6)
CD56+ Non metastatic ALNs (n = 9) 17.8 (15.8-52.8)(f) 0.437
Metastatic ALNs (n = 24) 18.3 (2.2-60.4)
  1. (a) ALNs: Axillary lymph nodes (paracortical areas: tumour deposits are excluded if present); (b) LLABCs: Large and locally advanced breast cancers; (c)NAC: Neoadjuvant chemotherapy; (d) PD-1+: Programmed death-1 (n = 16); (e)Average percentage of positively stained cells out of all the lymphoid cells in the ALN sections examined; (f) Average cell count of positively stained cells per 400× high-power field in the ALN sections examined; (g) Mann-Whitney U test